TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34056967

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS) at 2 mA for 20 minutes over the left dorsolateral prefrontal cortex the day after each match.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS) combined with recovery training session.
Number of subjects: 13
Study: 35477178

Group type: EXPERIMENTAL
Intervention: PAGGGM
Number of subjects: 20

Group type: COMPARATOR
Intervention: SAGM
Number of subjects: 20
Study: 34565444

Group type: EXPERIMENTAL
Intervention: TACUNA intervention (three virtual workshops utilizing motivational interviewing, social network visualization, and integrating traditional practices and a wellness circle)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Culturally sensitive opioid education workshop (control group)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: TACUNA intervention
Number of subjects: 370
Study: 35317789

Group type: EXPERIMENTAL
Intervention: Automated Treatment (AT), n=250, consisting of a fully-automated smartphone-based intervention with 10 weeks of nicotine replacement therapy (NRT) including transdermal patches and lozenges.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard Treatment (ST), n=250, connected to the Florida Quitline for telephone-based treatment and receiving a 10-week supply of nicotine replacement therapy (NRT).
Number of subjects: 500
Study: 32437501

Group type: EXPERIMENTAL
Intervention: Delayed targeted intraoperative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-breast radiotherapy
Number of subjects: 0
Study: 36228777

Group type: EXPERIMENTAL
Intervention: Medication first arm (n = 226)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Trabeculectomy first arm (n = 227)
Number of subjects: 453
Study: 32940393

Group type: EXPERIMENTAL
Intervention: Life History Calendar (LHC)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Retrospective diagnostic interview without LHC
Number of subjects: 1000
Study: 32453139

Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 0
Study: 35196954

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) applied before and after anastomosis (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n = 10) without RIC
Number of subjects: 22
Study: 34089546

Group type: EXPERIMENTAL
Intervention: Agomelatine (25–50 mg) with a guided sleep phase advance
Number of subjects: 15
Study: 32196772

Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid nanoemulsion (BF-200 ALA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hexyl aminolevulinate (HAL)
Number of subjects: 54
Study: 82282326

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 250 to 300 mg/d
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 500 to 600 mg/d
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 900 to 1000 mg/d
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 10 to 12 mg/kg body weight
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (all doses)
Number of subjects: 53
Study: 36075691

Group type: EXPERIMENTAL
Intervention: Unadjusted ferritin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Higher cut-off (HC) ferritin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Thurnham-corrected (TC) ferritin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Regression-corrected (RC) ferritin
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Baseline elevated iron status (HC ferritin)
Number of subjects: 400
Study: 32396205

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control
Number of subjects: 172
Study: 36107505

Group type: EXPERIMENTAL
Intervention: Turmeric-boswellia formulation (TBF) 1000 mg
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 36241767

Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Compensatory Strategy Training (CST)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All groups (APT, CST, Control)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Functional Impact Assessment (FIA)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Neuropsychological total mean T‐score
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: FACT-COG-PCI
Number of subjects: 65
Study: 33025648

Group type: EXPERIMENTAL
Intervention: 100 μg KLH immunization
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 μg KLH intradermal administration after immunization
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 32342883

Group type: EXPERIMENTAL
Intervention: SAVE training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35465983

Group type: EXPERIMENTAL
Intervention: H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later (Group 1)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Two doses of H7N9 IIV at three-week intervals after IIV4 alone (Group 2)
Number of subjects: 149

Group type: COMPARATOR
Intervention: One dose of IIV4 (Group 3)
Number of subjects: 149
Study: 33856155

Group type: EXPERIMENTAL
Intervention: Fiberglass prosthetic foot
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbon fiber prosthetic foot
Number of subjects: 10
Study: 35271306

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 824

Group type: COMPARATOR
Intervention: No bortezomib (Control)
Number of subjects: 824
Study: 32661703

Group type: COMPARATOR
Intervention: 2 mA tDCS
Number of subjects: 31

Group type: COMPARATOR
Intervention: 1 mA tDCS
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined antisaccade task and tDCS
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 31
Study: 32921090

Group type: EXPERIMENTAL
Intervention: Self-heating calf sleeves (SHCSs)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Control (no SHCSs)
Number of subjects: 557
Study: 34669059

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg/day)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 33162270

Group type: EXPERIMENTAL
Intervention: Decision Aids (DAs)
Number of subjects: 147

Group type: COMPARATOR
Intervention: No Decision Aids (Control)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: High pain self-efficacy
Number of subjects: 147
Study: 32066654

Group type: EXPERIMENTAL
Intervention: Sucrose-containing drinks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Non-nutritive sweeteners (NNS) containing drinks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unsweetened water
Number of subjects: 12
Study: 35241360

Group type: EXPERIMENTAL
Intervention: Over-the-counter diet pills
Number of subjects: 33824
Study: 33645377

Group type: EXPERIMENTAL
Intervention: Test 1 (0.413/0.050 mg/day E3/TMG)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Test 2 (0.311/0.090 mg/day E3/TMG)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Test 3 (0.209/0.137 mg/day E3/TMG)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Test 1
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Test 2
Number of subjects: 35
Study: 36401492

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) initiated when modified GCS score reached 13
Number of subjects: 296

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV) initiated when modified GCS score reached 15
Number of subjects: 296
Study: 35698158

Group type: EXPERIMENTAL
Intervention: 24-week regimen containing bedaquiline, pretomanid, and linezolid (arm 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-week regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (arm 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care arm (36 to 96 weeks duration)
Number of subjects: 0
Study: 32703562

Group type: EXPERIMENTAL
Intervention: High-density ventricular substrate mapping during sinus rhythm
Number of subjects: 10
Study: 35869145

Group type: EXPERIMENTAL
Intervention: Selumetinib every day (Arm A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Selumetinib days 1–5, 8–19 each cycle (Arm B)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine alone (Arm C)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Selumetinib (Arm A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Selumetinib (Arm B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Selumetinib-containing arms
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 51
Study: 33907099

Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine 1,000 mg/m2; twice daily for 14 days with oxaliplatin 130 mg/m2 on day 1, every 21 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: DX (capecitabine 1,000 mg/m2; twice daily for 14 days with docetaxel 75 mg/m2 on day 1, every 21 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 90

Group type: COMPARATOR
Intervention: DX
Number of subjects: 90
Study: 34857499

Group type: EXPERIMENTAL
Intervention: Virtual Classroom Training (VCT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Face-to-Face Training (FFT)
Number of subjects: 72
Study: 32591007

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) for 39 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual vocational services (UVS) for 39 weeks
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 108

Group type: COMPARATOR
Intervention: UVS
Number of subjects: 108
Study: 35658487

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice a day
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study: 34196464

Group type: EXPERIMENTAL
Intervention: Genetically predicted traits of heart rate variability (HRV) - RMSSD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted traits of heart rate variability (HRV) - pvRSA/HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically predicted traits of heart rate variability (HRV)
Number of subjects: 0
Study: 32535786

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 0
Study: 34013747

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg body wt‐1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Caffeine + Acetaminophen (Caffeine 5 mg·kg body wt‐1 + Acetaminophen 1,500 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,500 mg)
Number of subjects: 14
Study: 35414203

Group type: EXPERIMENTAL
Intervention: Tablet-based fatigue education and prescription program (FatigueUCope)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 279
Study: 34582548

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention with an energy-restricted Mediterranean diet plus physical activity (n = 190)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Nonrestrictive Mediterranean diet without physical activity (control; n = 201)
Number of subjects: 391
Study: 34749997

Group type: EXPERIMENTAL
Intervention: Reminiscing and Emotion Training (RET) intervention
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Family resources during the pandemic
Number of subjects: 137
Study: 32189094

Group type: EXPERIMENTAL
Intervention: Clozapine monitoring by an Advanced Nurse Practitioner (ANP)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Clozapine monitoring by a psychiatrist
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Clozapine monitoring by an ANP
Number of subjects: 173
Study: 34102418

Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz, 110% motor threshold, 1200 pulses/session) combined with daily gait training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham rTMS combined with daily gait training
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both active and sham TMS groups
Number of subjects: 58
Study: 32954301

Group type: EXPERIMENTAL
Intervention: Activity neurofeedback training
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Connectivity neurofeedback training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 32
Study: 36383362

Group type: EXPERIMENTAL
Intervention: D2 + No. 10 group
Number of subjects: 536

Group type: COMPARATOR
Intervention: D2 group
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: D2 + No. 10 group (advanced posterior gastric cancer)
Number of subjects: 536

Group type: COMPARATOR
Intervention: D2 group (advanced posterior gastric cancer)
Number of subjects: 536
Study: 33562699

Group type: EXPERIMENTAL
Intervention: Light–moderate walking outdoors (exercise condition)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Passive control condition (sitting and reading)
Number of subjects: 23
Study: 35197202

Group type: COMPARATOR
Intervention: CAC score of 781 (418–1467)
Number of subjects: 20207

Group type: COMPARATOR
Intervention: CAC score of 255 (162–394)
Number of subjects: 20207
Study: 33249244

Group type: EXPERIMENTAL
Intervention: Curettage group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Noncurettage group
Number of subjects: 80
Study: 35617674

Group type: EXPERIMENTAL
Intervention: Me & You curriculum
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 10
Study: 34432985

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 1719

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1719
Study: 32114477

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) plus metformin
Number of subjects: 120
Study: 35924574

Group type: EXPERIMENTAL
Intervention: Consultation (receiving information)
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Involvement (prioritizing risks)
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Partnership (identifying prevention actions)
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Home exercises
Number of subjects: 2403

Group type: COMPARATOR
Intervention: Two visits vs. one visit
Number of subjects: 2403

Group type: COMPARATOR
Intervention: Age ≥80 years
Number of subjects: 2403

Group type: COMPARATOR
Intervention: Fewer fall risk factors
Number of subjects: 2403
Study: 32273165

Group type: EXPERIMENTAL
Intervention: Half-columnar bone grafts from the ramus
Number of subjects: 46

Group type: COMPARATOR
Intervention: Rectangular bone grafts from the symphysis
Number of subjects: 46
Study: 35492335

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500 mg, 3 times daily for 5 days)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 32443433

Group type: EXPERIMENTAL
Intervention: Three whole Zespri® SunGold kiwifruit including the skin for 4 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Three whole Zespri® SunGold kiwifruit without the skin for 4 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Three whole Zespri® SunGold kiwifruit (with or without skin)
Number of subjects: 38
Study: 35167993

Group type: EXPERIMENTAL
Intervention: PEEP of 5 cmH2O until the end of mechanical ventilation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no PEEP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PEEP group
Number of subjects: 36
Study: 33798130

Group type: EXPERIMENTAL
Intervention: Phase-only authentication using single-pixel optical imaging through scattering media.
Number of subjects: 0
Study: 32845588

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570
Study: 35985028

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CHW intervention
Number of subjects: 24
Study: 33756503

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) level 120-140 mm Hg
Number of subjects: 12820

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) level 120-140 mm Hg (Group M)
Number of subjects: 12820

Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP) levels <100 mm Hg, 100-120 mm Hg, and ≥140 mm Hg
Number of subjects: 12820
Study: 32061140

Group type: EXPERIMENTAL
Intervention: Intranasally applied oxytocin (24 international units)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34728434

Group type: EXPERIMENTAL
Intervention: Suture button suspension (SBS)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ligament reconstruction and tendon interposition (LRTI)
Number of subjects: 76
Study: 34135449

Group type: EXPERIMENTAL
Intervention: Femtosecond-laser assisted cataract surgery (FLACS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Higher LOCS III cortical opacity quantifications
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nuclear opacities
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baseline qAF
Number of subjects: 60
Study: 32583975

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 84
Study: 34997835

Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination of Pitavastatin/Valsartan 4/160 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Individual components of Pitavastatin and Valsartan
Number of subjects: 54
Study: 33164570

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5103
Study: 35620920

Group type: EXPERIMENTAL
Intervention: Twelve-session lifestyle intervention delivered by Promotoras in Spanish.
Number of subjects: 615

Group type: COMPARATOR
Intervention: Six-session leadership training (control).
Number of subjects: 615
Study: 33587674

Group type: EXPERIMENTAL
Intervention: LipiFlow treatment in LipiFlow-surgery eye
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LipiFlow treatment in LipiFlow-nonsurgery eye
Number of subjects: 32

Group type: COMPARATOR
Intervention: LipiFlow-surgery eye
Number of subjects: 32

Group type: COMPARATOR
Intervention: nonLipiFlow-surgery eye
Number of subjects: 32
Study: 32604430

Group type: EXPERIMENTAL
Intervention: Music therapy (30 minutes daily)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (30 minutes of quiet time)
Number of subjects: 222
Study: 1994041002

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 250 mg twice a day
Number of subjects: 54
Study: 35383473

Group type: EXPERIMENTAL
Intervention: Family functioning improvement
Number of subjects: 203
Study: 32745686

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronate post hip fracture
Number of subjects: 0
Study: 35358154

Group type: EXPERIMENTAL
Intervention: 2-g bolus of tranexamic acid (TXA)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: 1-g bolus plus 1-g infusion of tranexamic acid (TXA) over 8 hours
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 33629488

Group type: EXPERIMENTAL
Intervention: Topical eflornithine cream twice daily for 16 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long‐pulsed Nd‐YAG laser for 4 sessions at 4-week intervals
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of topical eflornithine cream and long‐pulsed Nd‐YAG laser for 16 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follow-up after 12 weeks
Number of subjects: 40
Study: 35533263

Group type: EXPERIMENTAL
Intervention: NIRIS classification
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Stockholm CT score
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Rotterdam CT score
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Helsinki CT classification
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Marshall CT classification
Number of subjects: 882
Study: 34188067

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Prostate cancer‐free men from the general population)
Number of subjects: 0
Study: 32135143

Group type: EXPERIMENTAL
Intervention: Expedited partner therapy awareness
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Expedited partner therapy prescription received
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Willingness to dispense expedited partner therapy prescription
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Cost of azithromycin 1000 mg for treatment of chlamydia
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Cost of cefixime 400 mg for treatment of gonorrhea
Number of subjects: 335
Study: 35102440

Group type: EXPERIMENTAL
Intervention: maxgraft®
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Puros®
Number of subjects: 36
Study: 616774609

Group type: EXPERIMENTAL
Intervention: Abdominal application of traditional Chinese medicine combined with chewing gum
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine treatment and nursing care (Control)
Number of subjects: 108
Study: 35643684

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35641199

Group type: EXPERIMENTAL
Intervention: Well-formulated ketogenic diet (WFKD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mediterranean-plus diet (Med-Plus)
Number of subjects: 40
Study: 35143661

Group type: EXPERIMENTAL
Intervention: Time-lapse selection model for blastocyst transfer
Number of subjects: 776

Group type: COMPARATOR
Intervention: Morphology alone for blastocyst transfer
Number of subjects: 776
Study: 32543120

Group type: EXPERIMENTAL
Intervention: Edaravone 60 mg (therapeutic dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Edaravone 300 mg (supratherapeutic dose)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 27
Study: 32732587

Group type: EXPERIMENTAL
Intervention: Sliding hip screw
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cancellous screws
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91